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Practical Use and Risk of Modafinil, a Novel Waking Drug
Dongsoo Kim
Department of Basic Science, Air Force Academy, Cheongwon, Korea
Objectives: Modafinil is a waking drug prescribed to narcolepsy patients, but its usage among healthy individuals is increasing to enhance
their alertness or to mitigate fatigue. This study was conducted to investigate practical use and toxic effects on neuro-immune interaction of
modafinil.
Methods: This study reviewed the significance of psychoactive drugs, and discussed the benefits and risks of the application of modafinil,
which seems to be ideal as an anti-psychotic or anti-fatigue agent.
Results: Modafinil is known to have less or no adverse effects than those found in traditional psychostimulants such as amphetamine,
methylphenidate or cocaine. It can be applied as an anti-psychotic or anti-fatigue agent. However, the waking mechanism of modafinil is yet
to be fully revealed. Recent studies reported that modafinil may be subject to abuse and addiction. In addition prolonged sleeplessness
induces stress responses and impairs immune function. 
Conclusions: Modafinil can be used by anyone, who wishes to work late, stay awake, enhance their cognitive reactions, or brighten their
moods. Users may  already be under a great level of stress, i.e. cancer patients or soldiers in a battle field. A psychoneuroimmunological
approach is thus needed to investigate the multi-functional effects of modafinil.
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INTRODUCTION
Modafinil (2-[(diphenylmethyl) sulfinyl] acetamide) is an
exclusive psychostimulant with a waking effect, and is a
special medicine that can only be prescribed to shift workers
and patients suffering from narcolepsy or sleep apnea
(Figure 1)[1,2]. Modafinil has been commercialized as a
waking drug in 2003 [3]. The normal half-life of modafinil
in humans is between 12 to 15 hours [4]. Modafinil consists
of R-enantiomer and S-enantiomer as a racemic compound,
and the waking effect of R-enantiomer has a longer duration.
Moreover, Armodafinil, which is a R-enantiomer, was
commercialized as a waking drug [5,6]. Pharmacological
profile is notably different from the traditional
psychostimulants, such as amphetamines, cocaine or
methylphenidate. Modafinil is less related to side effects
such as excess locomotor activities, anxiety, jitteriness, or
rebound effects than the traditional stimulants [7]. It not only
has a waking effect but is also known for its mood-
brightening and memory-enhancing effects. Modafinil has
also been tried on disease-related fatigue, attention-deficit
disorder, Alzheimers s disease, age-related memory decline,
depression, idiopathic hypersomnia, cognitive impairment in
schizophrenia, myotonic dystrophy, post-anaesthesia
grogginess, everyday cat-napping, and jet-lag treatment [2,
8-12].
Modafinil is also of a high interest to the US military for
enhancing alertness and reducing battle fatigue [8,13,14].
Availability of modafinil as a lifestyle drug is increasing,
namely as a non-prescription medicine for healthy people.
More students or hard-working professionals will use it for a
late nights s work, if it can easily be purchased. In fact, it is
sold illegally in on-line shopping sites. Modafinil is distinct
from other psychostimulants in that it does not seem to
accompany any side effects, and this might encourage
healthy people to use it whenever they want to. However,
prolonged sleeplessness induces stress responses and impairs
immune functions [15]. Sleep-deprivation translocates
microbes from the gut to blood streams [16]. Animals
observed in sleep-deprivation experiments eventually
became victims of a massive bacterial infection in the blood.
The purpose of this review is to introduce practical
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Open Accessapplication of modafinil as an alertness-enhancing and anti-
fatigue drug, and to discuss pharmacological and
immunomodulatory effects of modafinil, of which the first
impression is harmless, even ideal.
PSYCHOSTIMULANTS
Psychoactive drugs are commonly classified into four
categories: tranquilizers, depressants, stimulants and
hallucinogens (Figure 2). However, the bounds of these
categories are not precisely delineated; rather, they have
several effects that overlap or combine into a new, different
one. Depressants and tranquilizers are used to relieve fear,
anxiety or excessive tension, while stimulants relieve
fatigue, stress or depression [9,17,18]. In particular,
stimulants along with depressants or tranquilizers are
medicated to treat sleep disorders or to maintain alertness for
an extended period [8,19]. However, most psychoactive
drugs have tolerance or dependence; in other words, they
bring about addiction in varying degrees. Thus, these
psychoactive drugs may cause problems when medicated
repeatedly or continuously. Despite the side effects of
psychoactive drugs, amphetamine and caffeine have been
traditionally used as alertness-enhancing or anti-fatigue
drugs.
Amphetamine, a kind of phenylethylamine, is a stimulant.
Amphetamine maintains alertness by inhibiting the reuptake
of norepinephrine and dopamine, and by that it stimulates
the secretion of catecholamines preserved in the vesicle of
neuronal cells [20]. The brains s reward circuits, which are
related to dopaminergic transmission, are involved in
pharmacological effects of amphetamine in the nervous
system [21]. However, amphetamine has an adverse
rebounding effect that causes depression or anxiety when the
intended effects wear off [22]. As a clinical medication,
amphetamine is used to treat traumatic brain injury, chronic
fatigue syndrome, attention deficit hyperactivity disorder
(ADHD), and hypnolesy [8,23,24]. It is also illegally
prescribed as a mood enhancer or as a waking drug for daily
life. Amphetamine is widely used for its comparative
effectiveness and lasting duration, but when abused it
becomes a highly addictive narcotic of rapid toleration rate
and increasing dependence [25].
Caffeine, a methylxantine derivative, has been used as a
psychoactive drug for a long period of time. For healthy
adults, the halflife of caffeine is 5 hours and it can be
extended up to 11 hours for pregnant women or women
taking birth control pills [26]. Caffeine acts as an antagonist
of adenosin receptors [27,28]. Pharmaceutically, caffeine is a
stimulant of metabolism and the central nervous system but
is also used as a lifestyle drug and a clinical drug to decrease
physical fatigue and maintain alertness. Caffeine capsules
brighten the mood for those with accumulated fatigue due to
lack of sleep and enhance concentration and task
performance. In daily life, caffeine is included in food or
drinks to help to improve alertness and to recover from
fatigue [29]. Medically, it is sold as a pill [8,19,24]. The
effectiveness and duration of caffeine are not as great as
amphetamine.
A novel class of psychostimulants is eugeroics under
which modafinil, adrafinil, and ampakine are categorized.
Eugeroic means good arousal; that is, eugeroics show no
sign of common side effects of traditional psychostimulants,




Figure 2.Classification of the psychoactive drugs.
NRIs, noradrenaline reuptake inhibitors; SSRIs, Selective serotonin reuptake inhibitors; MAOIs, Monoamine oxidase inhibitors; THC, Tetrahydrocannabinol;
DXM, Dextromethorphan; LSD, Lysergic acid diethylamide; DMT, Dimethyltryptamine; MDMA, Methylenedioxymethamphetamine.such as interference in recovery sleep, psychiatric
disturbance, and addiction [5,30,31].
PHARMACOLOGICAL MECHANISM OF
MODAFINIL
Modafinil has been clinically proven as an effective
medication in treating narcolepsy, a disabling neurological
disorder characterized by permanent and uncontrollable
daytime sleepiness. Orexin, which is a family of
wakefulness-promoting and sleep-inhibiting peptides, is
involved in inducing narcolepsy [32]. The orexin neurons
are found exclusively in the lateral hypothalamus and the
orexin neurons in the hypothalamic area projects to the entire
central nervous system [33]. Orexin neurons may be
activated by modafinil. Thus modafinil may induce
wakefulness by its action in the anterior hypothalamus [34].
However, the waking mechanism of modafinil on orexin
neurons yet to be fully elucidated. 
In a cat study, equal doses of amphetamine and
methylphenidate increased c-fos gene expression in entire
brain region including the caudate, but modafinil induced
selectively and prominently the c-fos expression in
hypothalamus of the brain [35]. Modafinil did not bind to
most receptors related to sleep and wake cycle and did not
inhibit monoamineoxidase or phosphodiesterase activities
[36]. However, some other mechanisms of waking effects
were proposed experimentally. Modafinil activates central
alpha 1-adrenergic receptor as an agonist [37]. The currently
proposed mechanism of modafinil suggests that modafinil
induces alertness through alpha-adrenergic receptor.
However, alpha-adrenergic transmission can not fully
explain why the alpha-adrenergic receptors in only a specific
part of the brain are activated for enhancing or maintaining
wakefulness. Modafinil inhibits the reuptake of noradrenalin
in the noradrenergic nerve endings. Therefore, the
noradrenalin signal between sleep-promoting neurons of
ventrolateral preoptic nucleus is amplified. An increase of
excitatory glutamatergic signaling by a decrease in the local
Ǳ -amino butyric acid transmission is also a significant effect
of modafinil [31,38,39]. Modafinil also amplifies cortical
serotonin release [40]. Amplification of the electro-
neurosecretory coupling mechanisms is preferentially
involved in serotonin release by modafinil, while via
reuptake process does not relate to serotonin release.
Modafinil increases histamine release significantly in the
anterior hypothalamus. However, modafinil did not induce
histamine release in the orexin knockout mice [41,42]. That
is, increase of histamine release by modafinil requires
orexinergic transmission.
It has been known that modafinil may not be involved in
dopamine release in the brain including the nuclear
accumbens [37,43], although it seems that modafinil
interacts with multiple molecular targets in the brain.
However, in a recent research, addictive potential of
modafinil has been reported [44,45]. There is substantial
evidence that modafinil, just like other addictive drugs, is
sensitive to dopamine signaling in the brain [30,45-47].
Modafinil preempts dopamine transporter (DAT) and
norepinephrine transporters in a living primate brain [44]. It
inhibits dopamine reuptake through DAT [48,49]. Therefore
modafinil administration increases extracellular levels of
dopamine in the brain [50-52], and wake-promoting actions
are absent in the DAT-knock-out mice [50]. Modafinil
blocks DAT and causes an increase of dopamine in the
animals and human brain including the nucleus accumbens,
thus inducing the same response as other waking drugs
[45,49,52]. An increase of dopamine in the nucleus
accumbens may be connected to drug abuse. The results of
the experiment mentioned above are insufficient for a
definitive evidence of addiction, since the main focus of
those experiments was not addiction. However, these results
lead to the possibility of addiction and have set the basis of
prohibition on long-term medication of modafinil.
APPLICATION FOR THE COUNTERMEASURE
OF FATIGUE
I. Anti-fatigue Agent for Cancer and Depression
Patients
Fatigue is a usual symptom among cancer patients, which
degrades their quality of life. Depression in cancer patients
may also come with tiredness. In regard to treatment of
cancer-related fatigue, methylphenidate has long been
studied to be very effective, despite its side effects [9,53].
Modafinil was also well-tolerated and effective against
fatigue in cancer patients when self-administrated for four
weeks [10]. The mood and quality of life of those patients
were improved. Modafinil has been applied effectively to
treat fatigue associated with depression, amyotropic lateral
sclerosis, and multiple sclerosis [11,54]. Modafinil is
effective in lowering the elevated fatigue level of cancer or
multiple sclerosis patients, but positive effects in cognitive
dysfunction associated with diseases are still controversial
[54,55].
II. Military Use of Modafinil as a Countermeasure of
Combat Fatigue 
Fatigue is a significant problem in a combat environment.
Combat fatigue come mainly from sleep deprivation caused
by extended duty periods, unpredictable work hours, circadian
disruption, fear, anxiety, and many more. Combat fatigue by
continuous sleep deprivation or sleep disorder can be
mitigated by medication. Pharmacological countermeasure is
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waking drugs for enhancing alertness and improving
psychomotor activities [26]. Modafinil along with the
traditional psychostimulants, such as amphetamines and
cocaine, has alertness-enhancing effect and mitigate the
accumulated fatigue in combat environment [13,14,27].
The effectiveness of caffeine, modafinil, and amphetamine
has been directly compared in a few studies, and the doses of
equal effectiveness in enhancing alertness and vigilance for
each of these three compounds were specified [22,27,56].
Administration of a single dose of caffeine 600 mg,
modafinil 400 mg, dextroamphetamine 20 mg, or placebo
after 44 hours of continuous wakefulness restored
psychomotor vigilance effectively compared to placebo in
healthy adults [27]. The duration of this effect was longest
for dextroamphetamine and shortest for caffeine. At above
doses, caffeine turned out to have the most  tsubjectively
reported side effectsu , followed by dextroamphetamine.
Dextroamphetamine was the only stimulant that had adverse
effects on subsequent recovery sleep. Modafinil did not
show significant, subjectively-reported side-effects nor
subsequent recovery sleep compared to placebo. The
effectiveness of these three stimulants is arranged in Table 1.
Modafinil is generally tolerated, and has few reported
cases of adverse events. Modafinil improves task
performance when medicated to people with normal living
patterns. It is also more effective than amphetamine [57].
Modafinil may become a lifestyle drug without a restriction
for narcoleptic patients. Also, the US military has shown
interest in modafinil for increasing alertness and helping
battle fatigue [8,13,14]. Moreover, when medicated to
people with fatigue and lethargic reactions as symptoms of
depression, modafinil generates a synergy by relieving
fatigue as well as depression [11]. Modafinil has a great
potential of becoming a combat-capability-enhancing drug
due to its waking, mood-brightening, and fatigue relieving
effects [2]. Elevated lethargy or fatigue under a combat
environment or war can be decreased by modafinil, and this
can also lead to an enhancement of combat capability
through an improvement in vigilance, psychomotor activity,
and self-regard. 
III. Adverse Effects
In early studies, it has been known that modafinil is a well
tolerated drug with a low probability of addiction. However,
the possibility of addiction in modafinil was reported in
recent papers mentioned above [44,45]. Modafinil induced
the elevation of dopamine level in the nucleus accumbens,
which could lead to drug abuse. Traditional waking drugs
elicit dopamine in the nucleus accumbens of the brain.
Modafinil increases dopamine in the nucleus accumbens
through inhibition of DAT in the animal and human brain as
other addictive waking drugs [44,49,52]. Classification of
modafinil as an addictive is still controversial. Modafinil
show possible setbacks of abuse and addiction even though
no cases have been reported to date [45]. The
pharmacological mechanism of modafinil must be further
elucidated. 
In general, we believe that sleep helps to build the immune
system. Sleep deprivation induces stress responses and
impairs immune functions [15,16]. However, reports for
immunomodulating effects of modafinil for keeping
wakefulness are quite limited. An investigation for
immunomodulation effects of modafinil is a significant step
in itself. The disruption of circadian rhythm and sleep
control may influence the neuro-immune circuits [32,33]. A
waking drug may have effects on neuro-immune circuits. If
someone, who is a non-narcoleptic patient, wants to use
modafinil for waking, enhancing their cognition, or
brightening his mood, they may already be under a high
level of stress, like soldiers in a battle field. It is possible that
modafinil seekers already face quite a stressful situation.
Stress responses via the hypothalamic-pituitary-adrenal axis
start from corticotropin-releasing hormone (CRH) [58,59].
The waking effect of modafinil is related to CRH [60].
Modafinil cannot be excluded from investigation for
immunomodulatory effects of stress. Serum C-reactive
protein level, which indicates the inflammation level of an
individual, was increased by a single dose of modafinil,
while it reduced host resistance to Listeria monocytogenes
infection [2].
Alertness-enhancing effect of modafinil may affect the
autonomic nervous system in the periphery [61,62].
Modafinil increases resting heart rate and blood pressure.
Modafinil elicits plasma and urine norepinephrine and urine
epinephrine. Modafinil may induce sympathomedullary
activation. Usage of modafinil could be restricted to patients
with heart disease because it causes excessive peripheral
autonomic activation. A few studies reported that modafinil
impairs recovery sleep under sleep deprivation, although
alertness-enhancing or cognitive-improving effect of
Environmental Health and Toxicology 2012; 27:e2012007
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a Duration of alertness-enhancing effect measured through psychomotor
vigilance test was 13.5 hours for amphetamine, 11.5 hours for modafinil,
and 5.5 hours for caffeine.
b More than 50% of caffeine group reported symptoms of nervousness,
excitation, abdomen pain, dry mouth, tremor, nausea, and jitteriness.
More than 50% of amphetamine group reported symptoms of excitation,
happiness, and dry mouth. Modafinil group was not significantly different












Nomodafinil is significant among sleep-deprived individuals
[12,63,64].
CONCLUSIONS
As modafinil gradually became known for its mood-
brightening and memory-enhancing effects along with its
waking effect, its usage has clearly increased as it is now
medicated to treat memory loss due to dementia, ADHD, jet
lag, and fatigue caused by extended work hours or illnesses.
Also modafinil can be used by anyone who wishes to work
late and/or concentrate for a long time. The demand for
drugs is high among those in competitive environments such
as high school students, examinees for new career
development, and athletes. If someone who is not a
narcoleptic patient wants to use modafinil for waking,
enhancing their cognition, or brightening their moods, they
may already be under great stress, like cancer patients or
soldiers in a battle field. A psychoneuroimmunological
approach is therefore needed to investigate multi-functional
effects of modafinil. A psychoneuroimmunological
approach may elucidate the immunomodulating effects of
modafinil in the aspect of communication between the
nervous and immune system.
In future studies, mechanism of modafinil will continue to
be examined because modafinil may generate possible abuse
and addiction and its waking mechanism has not been fully
elucidated [36,45]. Also, its medication guidelines have to be
revised because experiments on the dose and frequency of
modafinil have shown different results under multiple
simulations, and armodafinil, which is proven to be more
safe and effective, has been commercialized as a substituent
of modafinil.
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